HUE053244T2 - Opoid receptor (MOR) agonista só, fumarát só I kristályformája, és eljárás annak elõállítására - Google Patents
Opoid receptor (MOR) agonista só, fumarát só I kristályformája, és eljárás annak elõállításáraInfo
- Publication number
- HUE053244T2 HUE053244T2 HUE18784878A HUE18784878A HUE053244T2 HU E053244 T2 HUE053244 T2 HU E053244T2 HU E18784878 A HUE18784878 A HU E18784878A HU E18784878 A HUE18784878 A HU E18784878A HU E053244 T2 HUE053244 T2 HU E053244T2
- Authority
- HU
- Hungary
- Prior art keywords
- salt
- mor
- preparation
- crystal form
- opioid receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710242119 | 2017-04-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE053244T2 true HUE053244T2 (hu) | 2021-06-28 |
Family
ID=63792318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE18784878A HUE053244T2 (hu) | 2017-04-14 | 2018-04-13 | Opoid receptor (MOR) agonista só, fumarát só I kristályformája, és eljárás annak elõállítására |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11014914B2 (hu) |
| EP (1) | EP3610875B1 (hu) |
| JP (1) | JP7153030B6 (hu) |
| KR (1) | KR20190140962A (hu) |
| CN (1) | CN110049980B (hu) |
| AU (1) | AU2018251119B2 (hu) |
| BR (1) | BR112019021447A2 (hu) |
| CA (1) | CA3057383A1 (hu) |
| CY (1) | CY1124063T1 (hu) |
| DK (1) | DK3610875T3 (hu) |
| ES (1) | ES2828636T3 (hu) |
| HR (1) | HRP20210022T1 (hu) |
| HU (1) | HUE053244T2 (hu) |
| LT (1) | LT3610875T (hu) |
| MX (1) | MX2019012251A (hu) |
| MY (1) | MY196571A (hu) |
| PL (1) | PL3610875T3 (hu) |
| PT (1) | PT3610875T (hu) |
| RS (1) | RS61193B1 (hu) |
| SI (1) | SI3610875T1 (hu) |
| TW (1) | TWI682929B (hu) |
| UA (1) | UA124400C2 (hu) |
| WO (1) | WO2018188643A1 (hu) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018188641A1 (zh) * | 2017-04-14 | 2018-10-18 | 江苏恒瑞医药股份有限公司 | 一种mor激动剂与kor激动剂的药物组合物及其用途 |
| RS61193B1 (sr) * | 2017-04-14 | 2021-01-29 | Jiangsu hengrui medicine co ltd | So agonista opijatnog receptora (mor), kristalni oblik i fumaratne soli iste i postupak za njihovo dobijanje |
| WO2019205983A1 (zh) * | 2018-04-28 | 2019-10-31 | 四川科伦博泰生物医药股份有限公司 | 氧杂螺环类化合物及其制备方法和用途 |
| CN112638906B (zh) * | 2018-10-12 | 2022-05-27 | 江苏恒瑞医药股份有限公司 | 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法 |
| CN112638907B (zh) * | 2018-10-12 | 2022-04-12 | 江苏恒瑞医药股份有限公司 | 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法 |
| CN111662284B (zh) * | 2019-03-06 | 2021-08-10 | 上海海雁医药科技有限公司 | 双杂环取代的氧杂螺环衍生物、其制法与医药上的用途 |
| KR20210113824A (ko) | 2020-03-09 | 2021-09-17 | 건국대학교 산학협력단 | 뮤 오피오이드 수용체의 활성화제를 유효성분으로 포함하는 기분 장애의 예방용 조성물 |
| EP4361154A1 (en) * | 2021-07-13 | 2024-05-01 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Pharmaceutically acceptable salt of mor receptor agonist, and polymorph thereof and use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA025456B1 (ru) | 2011-03-23 | 2016-12-30 | Тревена, Инк. | Лиганды опиоидных рецепторов и способы их применения и получения |
| EP3354649B1 (en) | 2015-10-15 | 2019-12-04 | Jiangsu Hengrui Medicine Co., Ltd. | Oxa spiro derivative, preparation method therefor, and applications thereof in medicines |
| RS61193B1 (sr) * | 2017-04-14 | 2021-01-29 | Jiangsu hengrui medicine co ltd | So agonista opijatnog receptora (mor), kristalni oblik i fumaratne soli iste i postupak za njihovo dobijanje |
-
2018
- 2018-04-13 RS RS20201514A patent/RS61193B1/sr unknown
- 2018-04-13 SI SI201830176T patent/SI3610875T1/sl unknown
- 2018-04-13 CN CN201880004976.2A patent/CN110049980B/zh active Active
- 2018-04-13 ES ES18784878T patent/ES2828636T3/es active Active
- 2018-04-13 TW TW107112721A patent/TWI682929B/zh active
- 2018-04-13 HU HUE18784878A patent/HUE053244T2/hu unknown
- 2018-04-13 EP EP18784878.3A patent/EP3610875B1/en active Active
- 2018-04-13 BR BR112019021447A patent/BR112019021447A2/pt active Search and Examination
- 2018-04-13 LT LTEP18784878.3T patent/LT3610875T/lt unknown
- 2018-04-13 AU AU2018251119A patent/AU2018251119B2/en active Active
- 2018-04-13 UA UAA201911049A patent/UA124400C2/uk unknown
- 2018-04-13 DK DK18784878.3T patent/DK3610875T3/da active
- 2018-04-13 CA CA3057383A patent/CA3057383A1/en active Pending
- 2018-04-13 WO PCT/CN2018/082935 patent/WO2018188643A1/zh active Application Filing
- 2018-04-13 PT PT187848783T patent/PT3610875T/pt unknown
- 2018-04-13 JP JP2019555801A patent/JP7153030B6/ja active Active
- 2018-04-13 MX MX2019012251A patent/MX2019012251A/es unknown
- 2018-04-13 PL PL18784878T patent/PL3610875T3/pl unknown
- 2018-04-13 KR KR1020197033496A patent/KR20190140962A/ko active IP Right Grant
- 2018-04-13 US US16/499,453 patent/US11014914B2/en active Active
-
2019
- 2019-10-03 MY MYPI2019005849A patent/MY196571A/en unknown
-
2020
- 2020-10-22 CY CY20201101000T patent/CY1124063T1/el unknown
-
2021
- 2021-01-07 US US17/143,549 patent/US20210130332A1/en not_active Abandoned
- 2021-01-07 HR HRP20210022TT patent/HRP20210022T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3057383A1 (en) | 2018-10-18 |
| AU2018251119A1 (en) | 2019-11-07 |
| DK3610875T3 (da) | 2020-12-21 |
| AU2018251119B2 (en) | 2021-07-29 |
| US11014914B2 (en) | 2021-05-25 |
| LT3610875T (lt) | 2020-11-25 |
| CN110049980A (zh) | 2019-07-23 |
| ES2828636T3 (es) | 2021-05-27 |
| PL3610875T3 (pl) | 2021-04-19 |
| US20200048229A1 (en) | 2020-02-13 |
| RU2019136088A3 (hu) | 2021-06-16 |
| WO2018188643A1 (zh) | 2018-10-18 |
| HRP20210022T1 (hr) | 2021-03-05 |
| TWI682929B (zh) | 2020-01-21 |
| TW201837033A (zh) | 2018-10-16 |
| CN110049980B (zh) | 2020-10-20 |
| MX2019012251A (es) | 2019-11-28 |
| RU2019136088A (ru) | 2021-05-14 |
| JP2020516642A (ja) | 2020-06-11 |
| EP3610875A1 (en) | 2020-02-19 |
| KR20190140962A (ko) | 2019-12-20 |
| PT3610875T (pt) | 2020-11-25 |
| MY196571A (en) | 2023-04-19 |
| RS61193B1 (sr) | 2021-01-29 |
| JP7153030B6 (ja) | 2023-07-24 |
| CY1124063T1 (el) | 2022-03-24 |
| EP3610875A4 (en) | 2020-02-19 |
| SI3610875T1 (sl) | 2021-02-26 |
| UA124400C2 (uk) | 2021-09-08 |
| JP7153030B2 (ja) | 2022-10-13 |
| BR112019021447A2 (pt) | 2020-05-05 |
| EP3610875B1 (en) | 2020-10-07 |
| US20210130332A1 (en) | 2021-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3610875T1 (sl) | Sol agonista opioidnega receptorja (MOR), kristalna oblika I fumaratne soli le-tega in postopek za pripravo le-te | |
| IL283362A (en) | A thrbeta receptor agonist compound and a method for its preparation and use | |
| IL287166A (en) | A pyrazolopyridine derivative with an agonistic effect on the glp-1 receptor | |
| EP3650449A4 (en) | FXR RECEPTOR AGONIST | |
| HK1259170A1 (zh) | 一種tlr7激動劑的晶型a、其製備方法和用途 | |
| EP3675837A4 (en) | LOW TEMPERATURE STABLE OPIOID ANTAGONIST SOLUTIONS | |
| HK1259175A1 (zh) | 一種tlr7激動劑的馬來酸鹽、其晶型c、晶型d、晶型e及其製備方法和用途 | |
| HK1259182A1 (zh) | 一種tlr7激動劑的三氟乙酸鹽、晶型b、製備方法和用途 | |
| SG11201608372PA (en) | Irinotecan hydrochloride composite phospholipid composition, preparation method and use thereof | |
| GB201522431D0 (en) | Novel glp-1 receptor agonist peptides | |
| PL3495352T3 (pl) | Postacie krystaliczne antagonisty receptora androgenowego, ich sposób wytwarzania i zastosowanie | |
| EP3305316A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SARCOPENIA COMPRISING A PEPTIDE-1 RECEPTOR AGONIST SIMILAR TO GLUCAGON | |
| EP3269710A4 (en) | Nintedanib diethanesulfonate salt crystal and preparation method and use thereof | |
| HK1231414A1 (zh) | 胃輕癱用 受體激動劑 | |
| EP3336088A4 (en) | CRYSTALLINE FORM OF THE OREXIN RECEPTOR ANTAGONIST COMPOUND, PREPARATION METHOD AND APPLICATION THEREOF | |
| PT3216791T (pt) | Substância polimórfica de cloridrato de yonkenafil, método de preparação e composição e uso da mesma | |
| EP3461823A4 (en) | PLX3397 HYDROCHLORIDE CRYSTAL FORM, MANUFACTURING METHOD AND USE THEREOF | |
| ME03062B (me) | Nova sol ivabradina sol i postupak njegove pripreme | |
| PT3247719T (pt) | Proteínas agonistas do receptor met | |
| PT3303297T (pt) | Novo método para a preparação de base de ivabradina de elevada pureza e sais da mesma | |
| ZA201504398B (en) | Pharmaceutical composition comprising ivabradine hydrochloride and method for preparation thereof |